Clinical trials: Nevirapine
HIV Infections
Observational Study With Antiretroviral Treated Patients Switching to Nevirapine Plus Two Nucleoside Reverse Transcriptase Inhibitor (NRTI) Regimens
Collecting data on maintaining anti-retroviral activity (quantitative HIV RNA determination) and immunological activity (CD4 cells) after switching from protease inhibitor or NNRTI to Nevirapine (Viramune®) and collecting of…
- Trial name
- NCT02191319
- Testing
- Viramune®
- Volunteers
- 55 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Pharmacokinetic Interaction Between Nevirapine and Saquinavir-sgc in HIV-1 Infected Patients
The objectives of this study are to determine the effects of nevirapine on the steady-state pharmacokinetics of saquinavir-sgc and to determine the effects of saquinavir-sgc on the steady-state pharmacokinetics of nevirapine.
- Trial name
- NCT02184286
- Testing
- Nevirapine, Saquinavir-sgc
- Volunteers
- 5 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Nevirapine Resistance Study: Nevirapine Resistance Among HIV-Infected Mothers
The purpose of this study is to determine whether the addition of zidovudine (ZDV) and lamivudine (3TC) at the onset of labor and for up to seven days postpartum to single-dose nevirapine (NVP) is associated with a lower…
- Trial name
- NCT00164762
- Where
- Malawi
- Volunteers
- 126 people
- Sponsor
- Centers for Disease Control and Prevention
HIV Infections
An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease
To provide access to Viramune and to evaluate the tolerance and safety of Viramune in patients with progressive, symptomatic HIV disease who failed or are intolerant to currently approved treatment for HIV-1 infection and who are…
- Trial name
- NCT00002166
- Testing
- Nevirapine
- Where
- United States
- Sponsor
- Boehringer Ingelheim
HIV Infections
Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya
Globally, children who acquire HIV-1 increasingly do so in the context of maternal antiretroviral prophylaxis. It is important to determine whether maternal antiretroviral prophylaxis should alter infant treatment regimens.
- Trial name
- NCT00427297
- Testing
- AZT/3TC/NVP (zidovudine/lamivudine/nevirapine), d4T/3TC/NVP (stavudine/lamivudine/nevirapine), AZT/3TC/ABC (zidovudine/lamivudine/abacavir)
- Where
- Kenya
- Volunteers
- 34 people
- Sponsor
- University of Washington
HIV Infections
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
The purpose of this study is to see if it is safe and effective to give a new anti-HIV drug combination to HIV-infected patients who have never taken nonnucleoside reverse transcriptase inhibitors (NNRTIs) and who have failed to…
- Trial name
- NCT00002418
- Testing
- Emivirine, Hydroxyurea, Nevirapine
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Genetic Determinants of the Metabolism of Non-nucleoside Reverse Transcriptase Inhibitors
To see if certain variations in the CYP2B6 gene contribute to differences in plasma drug levels and central nervous system side affects in people who take nevirapine or efavirenz.
- Trial name
- NCT00730223
- Testing
- Nevirapine and Efavirenz
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
HIV Infections, Tuberculosis
Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients
There are increasing numbers of HIV-infected patients in sub-Saharan Africa receiving antiretroviral drugs and/or rifampicin based antituberculous therapy. HIV infected patients are at an increased risk of contracting malaria.
- Trial name
- NCT00620438
- Testing
- Lumefantrine-artemether and nevirapine, lumefantrine-artemether and efavirenz, Lumefantrine-artemether and rifampicin
- Where
- Uganda
- Volunteers
- 90 people
- Sponsor
- Makerere University
NVP Plasma Level, NVP Related Mutation
Nevirapine Clearance After Short-term Highly Active Antiretroviral Therapy (HAART) for Prevention of Mother to Child Transmission of HIV (PMTCT)
Three-drug combination of antiretroviral regimens has been used increasingly in HIV-infected pregnant women worldwide, both for the prevention of mother to child transmission of HIV (PMTCT) and for women's own health.
- Conditions
- NVP Plasma Level, NVP Related Mutation, 3TC Related Mutation
- Trial name
- NCT00872872
- Testing
- AZT/3TC 2 weeks after delivery
- Where
- Thailand
- Volunteers
- 30 people
- Sponsor
- Thai Red Cross AIDS Research Centre
HIV Infections
Safety and Pharmacokinetic Study of Fixed Dose Combination of Zidovudine, Lamivudine, and Nevirapine in HIV-Infected Children in Thailand
In 2005, there were 50,620 HIV-infected children living in Thailand. Current anti-HIV regimens, comprised of individual pills for each drug, frequently lead to missed doses.
- Trial name
- NCT00672412
- Testing
- GPO-Vir Z30 tablet, Lamivudine, Nevirapine
- Where
- 4 sites in Thailand
- Volunteers
- 42 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment
The purpose of this study is to determine the value of changing anti-HIV medications in children with progressive HIV disease who have received previous treatment.
- Trial name
- NCT00000902
- Testing
- Ritonavir, Nelfinavir mesylate, Nevirapine
- Where
- 62 sites in United States, Puerto Rico
- Volunteers
- 217 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Trial About Hepatic Security of Antiretroviral Treatment Based on Kaletra Versus Nevirapine in Co-infected HIV/HCV Patients
In retrospective studies, acceleration of hepatic fibrosis has been seen in Nevirapine (NVP) treatment when compared with Protease Inhibitors (PI) boosted with ritonavir treatment in patients with Human Immunodeficiency Virus…
- Trial name
- NCT00661349
- Testing
- Lopinavir/ritonavir, Nevirapine
- Where
- 9 sites in Spain
- Volunteers
- 9 people
- Sponsor
- Germans Trias i Pujol Hospital
HIV Infections, Tuberculosis
Efficacy Safety Study Comparing 2 Doses of NVP After Initiating Rifampin-containing TB Therapy
A 48 week, randomized, open-label, two arm study to compare the efficacy, safety and tolerability of HAART containing nevirapine 400 mg/day versus nevirapine 600 mg/day in HIV-1 infected patients started at 2-6 weeks after…
- Trial name
- NCT00476853
- Testing
- HAART containing nevirapine
- Where
- 6 sites in Thailand
- Volunteers
- 42 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
HIV
Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir
The study will be an open-label, pilot study in virologically suppressed patients comparing the efficacy, safety and tolerability of two Antiretroviral regimen strategies: Arm A: "Immediate switch"…
- Trial name
- Near-Rwanda (NCT02104700)
- Testing
- Rilpivirine/Emtricitabine/Tenofovir
- Where
- Rwanda
- Volunteers
- 150 people
- Sponsor
- Philip Grant
Acquired Immunodeficiency Syndrome
Pharmacokinetic Study of Interaction Between Nevirapine and Methadone in HIV-1 Infected, Opioid-dependent Adults
The purpose of this study was to determine the effects of nevirapine treatment on the pharmacokinetics of methadone in HIV-1 infected, opioid-dependent adults who had been on a stable methadone maintenance therapy for at least…
- Trial name
- NCT00273988
- Testing
- nevirapine
- Where
- Ireland
- Volunteers
- 10 people
- Sponsor
- Boehringer Ingelheim
Renal Insufficiency, Hepatic Insufficiency
Study to Evaluate the Effects of Underlying Renal or Hepatic Dysfunction on the Pharmacokinetics of Nevirapine
Study to assess the effects of varying degrees of renal dysfunction and hepatic insufficiency on the single-dose pharmacokinetics of nevirapine and nevirapine metabolites in order to establish an appropriate dose and/or dosing…
- Trial name
- NCT02184091
- Testing
- Nevirapine
- Volunteers
- 41 people
- Sponsor
- Boehringer Ingelheim
HIV Infections, Lipodystrophy
Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients
The goals of this study are to find out if fat wasting and weight loss in the arms and legs of HIV patients taking highly active antiretroviral therapy (HAART) are caused by nucleoside/nucleotide reverse transcriptase inhibitors…
- Conditions
- HIV Infections, Lipodystrophy, Wasting Disease
- Trial name
- NCT00028314
- Testing
- Abacavir sulfate, Atazanavir/Ritonavir, Lopinavir/Ritonavir
- Where
- 25 sites in United States
- Volunteers
- 150 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
An Open-Label, Pilot Study to Evaluate the Development of Resistance to Nevirapine (BI-RG-587) in HIV-Infected Patients With CD4 Cell Count >= 500/mm3
Primary: To evaluate the rate of development of resistance to nevirapine in HIV-1 infected individuals. To evaluate safety of nevirapine in HIV-1 infected individuals with CD4 counts greater than or equal to 500 cells/mm3.
- Trial name
- NCT00000747
- Testing
- Nevirapine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection
The purpose of this study is to compare the effectiveness, safety, and tolerability of 3 anti-HIV combination treatments that do not use protease inhibitors (PIs).
- Trial name
- NCT00013520
- Testing
- Abacavir sulfate, Lamivudine and Zidovudine, Atazanavir, Lamivudine/Zidovudine
- Where
- 60 sites in United States, Puerto Rico
- Volunteers
- 1,125 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Viramune® in HIV-1 Infected Subjects
The objective was to establish the pharmacokinetic (PK) profile at steady state of two different nevirapine (NVP) extended release (XR) formulations at 300 mg or 400 mg daily (QD) under fasted and fed conditions in comparison…
- Trial name
- NCT02194179
- Testing
- NVP XR 400 mg (KCR 25%), NVP XR 400 mg (KCR 20%), NVP XR 300 mg (KCR 25%)
- Volunteers
- 92 people
- Sponsor
- Boehringer Ingelheim